Followers | 11 |
Posts | 498 |
Boards Moderated | 0 |
Alias Born | 10/07/2013 |
Saturday, August 30, 2014 7:02:31 AM
As always, the devil is in the detail with Qiu's 2014 article (link) on reversing Ebola disease with zMapp up to 5 days post infection...
Don't count on news reporters to notice them.
In short, these apparently great results are to ponder in view of lower virus exposure and near double doses of treatment...
Recall ZMapp is a combo of 2 MAbs from ZMabb and 1 from MB-003 (underlined below), that all target EBOV's GP (surface Glyco-Protein).
-- Experiment 1
50 mg/ kg of ZMapp (13C6, 2G4, 4G7 MAb combo) or ZMapp2 (13C6, 1H3, 2G4 MAb combo) every 3 days following infection by 2,512 PFU EBOV.
Survival was 100% (6/6) if initiated on day 3 for ZMapp1 and 83% (5/6) for ZMApp2.
-- Experiment 2
50 mg/ kg of ZMapp every 3 days following infection by 628 PFU EBOV.
Survival was 100% (6/6) if initiated on day 3.
Survival was 100% (6/6) if initiated on day 4.
Survival was 100% (6/6) if initiated on day 5.
Going into prior data on the components of ZMapp:
In 2012, Qiu gave 25 mg/kg of ZMabb (1H3, 2G4, 4G7 MAb combo) every 3 days following infection by 1,000 PFU EBOV.
Survival was 100% (4/4) if initiated 24 hrs post infection.
Survival was 50% (2/4) if initiated at 48 hrs post infection.
In 2012, Olinger gave 50 mg/kg of MB-003 (13C6, 13F6, 6D8 MAb combo) 4 times following infection by 1,000 PFU EBOV.
Survival was 67% (2/3) if initiated 24 hrs post infection.
Survival was 67% (2/3) if initiated 48 hrs post infection.
Recent ABUS News
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/08/2024 08:17:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:13:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 11:31:17 AM
- Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 07/18/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:16:15 PM
- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels • GlobeNewswire Inc. • 06/06/2024 03:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 10:00:21 AM
- Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure • GlobeNewswire Inc. • 06/05/2024 06:30:00 AM
- Arbutus to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:25:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:10:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:07:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 10:00:18 AM
- Arbutus to Present Imdusiran Data at EASL Congress 2024 • GlobeNewswire Inc. • 05/22/2024 06:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 01:03:23 PM
- Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value • Business Wire • 05/17/2024 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/09/2024 12:00:20 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 11:30:00 AM
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 • GlobeNewswire Inc. • 05/02/2024 11:25:00 AM
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna • GlobeNewswire Inc. • 04/04/2024 12:30:49 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM